Comparison
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690 vs 4 Hydroxyphenyllactic Aciduria C1848679
Clinical comparison between 46 XY Disorder OF Sexual Development Due TO Dihydrotestosterone Backdoor Pathway Biosynthesis Defect and 4 Hydroxyphenyllactic Aciduria for differential diagnosis and treatment planning.
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
A rare enzyme defect affecting an alternative pathway for making dihydrotestosterone, a hormone important for male genital development. This can cause undervirilization. Treatment may include hormone therapy.
4 Hydroxyphenyllactic Aciduria C1848679
A metabolic condition affecting how the body processes amino acids. Usually identified in early life. Managed through specialized diet and regular medical follow-up.
6 comparison axes
Onset
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
0-0
4 Hydroxyphenyllactic Aciduria C1848679
Variable
Onset patterns differ
Severity
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
severe
4 Hydroxyphenyllactic Aciduria C1848679
moderate
Different severity levels
Chronic
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
Chronic
4 Hydroxyphenyllactic Aciduria C1848679
Chronic
Differing course
Communicable
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
No
4 Hydroxyphenyllactic Aciduria C1848679
No
Different transmission
Body System
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
reproductive
4 Hydroxyphenyllactic Aciduria C1848679
metabolic
Same/different system
Category
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
endocrine
4 Hydroxyphenyllactic Aciduria C1848679
metabolic
Different category
Bottom line
46-xy-disorder-of-sexual-development-due-to-dihydrotestosterone-backdoor-pathway-biosynthesis-defect-C5816690 and 4-hydroxyphenyllactic-aciduria-C1848679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690 | 4 Hydroxyphenyllactic Aciduria C1848679 | Discriminating power |
|---|---|---|---|
| Main clinical domain | 46,XY undervirilization linked to impaired alternative DHT synthesis | Amino-acid processing abnormality; not a genital-development diagnosis | High |
| Recognition timing | Expected from birth or early genital assessment | Variable; often considered during early-life metabolic testing | Moderate |
| Care focus | Endocrine and reproductive evaluation; hormone therapy may be considered | Metabolic follow-up and a specialized diet when indicated | High |
When to favor each condition
Choose 46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690 when
46,XY infant with undervirilization
The phenotype matches the described DHT-pathway disorder, pending specialist confirmation
Moderate
Suspected disorder of sexual development
The supplied classification is reproductive and endocrine rather than dietary-metabolic
High
Planning endocrine management
Source information mentions possible hormone therapy, not dietary treatment
Moderate
Choose 4 Hydroxyphenyllactic Aciduria C1848679 when
Metabolic testing suggests 4-hydroxyphenyllactic aciduria
This points to an amino-acid-related finding or condition, distinct from DSD
Moderate
Early-life metabolic evaluation
The source states it is usually identified in early life, although onset is variable
Moderate
Considering dietary metabolic care
Management is described as specialized diet plus regular follow-up
Moderate
How key tests differ
| Test | 46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690 | 4 Hydroxyphenyllactic Aciduria C1848679 | Interpretation |
|---|---|---|---|
| Genital and endocrine assessment | Findings may support undervirilization in a 46,XY infant | No genital-development abnormality is established by the source | Abnormal anatomy does not diagnose the enzyme defect without specialist testing |
| Hormone pathway evaluation | Assessment targets alternative DHT biosynthesis | Not the primary described investigation | Specific cutoffs and enzyme results are not supplied and require clinician interpretation |
| Amino-acid or organic-acid testing | Not described as characteristic | May show the named metabolic abnormality | An abnormal metabolite is not automatically a complete diagnosis |
Prognosis comparison
46 Xy Disorder Of Sexual Development Due To Dihydrotestosterone Backdoor Pathway Biosynthesis Defect C5816690
- Outcome
- Long-term outcome is not established; labeled severe and chronic
- Factors
- Degree of undervirilization, endocrine findings, and response to specialist care
4 Hydroxyphenyllactic Aciduria C1848679
- Outcome
- Long-term outcome is not established; labeled moderate and chronic
- Factors
- Metabolic control, dietary adherence, and associated findings
Time frame: From early life into ongoing follow-up; exact course is not established
Accurate diagnosis, specialist monitoring, and avoidance of unsupported treatment changes
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental effects | Undervirilization may affect genital development No specific developmental complication is established Individual severity and associated findings need specialist assessment |
| Metabolic imbalance | Not described Possible consequence of disordered amino-acid processing Exact complications, thresholds, and frequency are not established here |
| Long-term health needs | Chronic endocrine and reproductive follow-up may be needed Chronic dietary and metabolic monitoring may be needed These needs differ and should not be interchanged |
Patient education highlights
- HighDifferent conditions
One concerns male genital hormone development; the other concerns amino-acid metabolism. A clinician must confirm which applies.
- HighNo self-directed treatment
Do not start, stop, or change hormones or diet without specialist advice. Doses and cutoffs are not established here.
- MediumFollow-up
Both are described as chronic and benefit from planned specialist review and family counseling.